GlassScriptPhysician profile
Lawrence W Gooss
NPI 1508092487
$4,187.15
in general payments reported to CMS, 2019-2025
40 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $19.92 · 2022: $12.32 · 2023: $272 · 2024: $1,878 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $511.95 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $480.38 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $460.05 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $430.13 | 2022-2025 | |
| Abbott Laboratories | $308.12 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $274.45 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $199.93 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $124.93 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.24 | 2023-2024 | Jardiance, Tradjenta |
| Irhythm Technologies, INC. | $113.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $107.14 | 2024-2025 | |
| Amgen INC. | $80.69 | 2024-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.28 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $74.35 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $71.81 | 2024-2025 | Ajovy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $69.57 | 2024 | Tryvio |
| Inspire Medical Systems, INC. | $61.45 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $55.00 | 2023-2025 | Gardasil 9, Gardasil, Pneumovax 23 |
| Dynavax Technologies Corporation | $53.62 | 2023-2024 | Heplisav-B |
| Exact Sciences Corporation | $49.41 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $41.65 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $39.62 | 2024 | Auvelity |
| Philips North America LLC | $35.81 | 2024 | (Ck6) Holter |
| Otsuka America Pharmaceutical, INC. | $34.01 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $31.23 | 2024 | |
| Boston Scientific Corporation | $29.58 | 2024 | Watchman Flx |
| Vanda Pharmaceuticals INC. | $27.87 | 2025 | Fanapt |
| Hologic Sales and Service, LLC | $22.85 | 2025 | Aptima, Thinprep 2000 Processor |
| Impulse Dynamics (USA) INC. | $21.53 | 2023 | Optimizer |
| Kyowa Kirin, INC. | $21.06 | 2024 | Nourianz |
| Astellas Pharma US INC | $20.78 | 2025 | Veozah |
| Noven Therapeutics, LLC | $20.71 | 2024 | Xelstrym, Secuado |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.74 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $16.40 | 2024 | |
| Antares Pharma, INC. | $15.61 | 2025 | Xyosted |
| Biogen, INC. | $14.60 | 2024 | Leqembi |
| Actelion Pharmaceuticals US, INC. | $14.48 | 2024 | Opsumit, Uptravi |
| Amneal Pharmaceuticals LLC | $13.75 | 2025 | Unithroid |
| Eisai INC. | $13.46 | 2024 | |
| Lundbeck LLC | $13.35 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Gooss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.